Libtayo is an antibody targeting the immune checkpoint receptor PD-1 and is the only treatment approved in advanced cutaneous squamous cell carcinoma in the European Union, it said.
Price: 315.51, Change: +2.51, Percent Change: +0.80
|Wall Street Sees Narrowly Mixed Open Ahead of Rate D...|
|Analyst Actions: UBS Lifts AutoZone's Price Target t...|
|Sector Update: Top Consumer Stocks Mostly Gain Pre-B...|
|--Analyst Actions: Credit Suisse Raises AutoZone's P...|
|Analyst Actions: Nomura Raises AutoZone's Price Targ...|